Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 17/20 | 0.74 |
| ▸ | HTR2C | P28335 | 7/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.48 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.48 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.48 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2064056 | 0.90 | HTR2A (0.79) | HTR2AHTR2CKCNH2KCNQ3KCNQ2 | |
| SCHEMBL2065040 | 0.90 | HTR2A (0.78) | HTR2AHTR2CKCNH2KCNQ3KCNQ2 | |
| SCHEMBL884514 | 0.87 | HTR2A (0.75) | HTR2AHTR2CKCNH2KCNQ3KCNQ2 | |
| SCHEMBL18969777 | 0.86 | HTR2A (0.74) | HTR2AHTR2CKCNH2KCNQ3KCNQ2 | |
| SCHEMBL2064110 | 0.86 | HTR2A (0.81) | HTR2AHTR2CKCNH2 | |
| SCHEMBL15788651 | 0.85 | HTR2A (0.85) | HTR2AHTR2CKCNH2KCNQ3KCNQ2 | |
| SCHEMBL1166820 | 0.85 | HTR2A (0.71) | HTR2AHTR2CKCNH2 | |
| SCHEMBL883993 | 0.85 | HTR2A (1.00) | HTR2AHTR2CKCNH2 | |
| SCHEMBL885600 | 0.85 | HTR2A (0.72) | HTR2AHTR2CKCNH2KCNQ3KCNQ2 | |
| SCHEMBL883994 | 0.85 | HTR2A (0.73) | HTR2AHTR2CKCNH2KCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247755-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-08-06 | — | — | US | disclosed |
| US-10450276-B2 | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20170166533-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-9221755-B2 | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150174102-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT 2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-RE45337-E1 | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140163032-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT 2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-8680119-B2 | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120295938-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2012-11-22 | — | — | US | disclosed |
| US-8148418-B2 | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090186895-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174102-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT 2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HTR2C 3/4885KCNH2 1047/4885 |
| US-20170166533-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HTR2C 3/4885KCNH2 1018/4885 |
| US-20090186895-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HTR2C 3/4885KCNH2 1018/4885 |
| US-10450276-B2 | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HTR2C 3/4885KCNH2 1018/4885 |
| US-20200247755-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HTR2C 3/4885KCNH2 1018/4885 |
| US-20140163032-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT 2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HTR2C 3/4885KCNH2 737/4885 |
| US-20120295938-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HTR2C 3/4885KCNH2 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.